Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2008, vol. 17, nr 5, September-October, p. 513–518

Publication type: original article

Language: English

Beneficial Effect of Dexmedetomidine on Testicular Ischemia – Reperfusion Injury in Rats

Korzystny wpływ deksmedetomidyny na niedokrwienie jąder – uszkodzenie reperfuzyjne u szczurów

Hakan Terzi1,, Hulya Ozturk2,, Guler Bugdayci3,, Hayrettin Ozturk4,

1 Departments of Histology and Embryology1, Biochemistry3, and Pediatric Surgery4, Medical School, Abant Izzet Baysal University, Bolu, Turkey

2 Department of Pediatric Surgery, Medical School, Duzce University, Duzce, Turkey

3 Department of Biochemistry, Medical School, Abant Izzet Baysal University, Bolu, Turkey

4 Department of Pediatric Surgery, Medical School, Abant Izzet Baysal University, Bolu, Turkey

Abstract

Background/
Background. Objectives.
Objectives. The present study was designed to determine the beneficial effect of dexmedetomidine (Dex) on torsion−detorsion−induced histopathological changes in experimental testicular ischemia/reperfusion (I−R) injury in rats.
Material and Methods. Twenty−one male Sprague−Dawley rats were separated into three groups of seven rats each. A sham operation was performed in group 1 (control). In group 2 (I−R/Untreated), unilateral testicular torsion was performed for 6 h followed by 1 h of detorsion of the testis. In group 3 (I−R/Dex), after performing the same procedures as in group 2, dexmedetomidine was given intravenously. Ipsilateral orchidectomies were performed in all experimental rats for histological examination. The levels of MDA and activities of SOD and CAT were measured in the testicular tissue.
Results. MDA levels were higher in group 2 than in group 1 rats and lower in group 3 than in group 2. SOD and CAT activities were higher in group 3 than in group 2 rats. Histopathologically, in the group 2 rats the lesions varied between grades III and IV and edema, congestion, hemorrhage between seminiferous tubules, and necrosis of the germinal cells were predominant features in sections. However, most of the specimens in the dexmedetomidine−treated group 3 showed grades I and II injury. The testicular injury score was also lower in group 3 rats than in group 2.
Conclusion. The results show that dexmedetomidine may play a protective role in reducing injury caused by I−R.

Streszczenie

Wprowadzenie/
Wprowadzenie. Cel pracy.
Cel pracy. Ocena korzystnego wpływu deksmedetomidyny (Dex) na zmiany histopatologiczne w wyniku skręcenia jąder w eksperymentalnym niedokrwieniu – uszkodzeniu reperfuzyjnym (I−R) u szczurów.
Materiał i metody. 21 szczurów szczepu Sprague−Dawley płci męskiej podzielono na 3 grupy po 7 osobników. Wgrupie I (kontrolnej) przeprowadzono operację pozorną. W grupie 2 (I−R/bez leczenia) uwalniano skręt jądra na godzinę. W grupie 3 (I−R/Dex) po przeprowadzeniu takiej samej operacji jak w grupie 2 podawano deksmedetomidynę dożylnie. U wszystkich szczurów doświadczalnych przeprowadzono jednostronną orchidektomię w celu przeprowadzenia badań histologicznych. W tkance jądra badano stężenie MDA i aktywność SOD i CAT.
Wyniki. Stężenie MDA było większe w grupie 2 niż w 1. W grupie 3 stężenie MDA było mniejsze niż w grupie 2. Aktywność SOD i CAT była większa w grupie 3 niż w grupie 2. W grupie 2 wykryto zmiany histopatologiczne III–IV stopnia. W badanych preparatach dominowały: obrzęk, przekrwienie, zmiany krwotoczne oraz martwica komórek zarodkowych. Chociaż większość próbek z grupy 3 leczonej deksmedetomidyną wykazała zmiany I–II stopnia, to wynik oceny punktowej uszkodzenia jąder był niższy w grupie 3 niż w grupie 2.
Wnioski. Badania pokazały, że deksmedetomidyna może odgrywać rolę ochronną w zmniejszaniu uszkodzeń spowodowanych przez I−R.

Key words

testicular torsion, ischemia−reperfusion, dexmedetomidine, rat

Słowa kluczowe

skręcenie jąder, niedokrwienie – reperfuzja, deksmedetomidyna, szczur

References (38)

  1. Can C, Töre F, Tunçel N, Uysal O, Gürer F, Ak D, Tunçel M: Protective effect of vasoactive intestinal peptide on testicular torsion−detorsion injury: association with heparin−containing mast cells. Urology 2004, 63, 195–200.
  2. Anderson JB, Williams RC: Fertility after torsion of spermatic cord. Br J Urol 1990, 65, 225–230.
  3. Filho DW, Torres MA, Bordin AL, Crezcynski−Pasa TB, Boveris A: Spermatic cord torsion, reactive oxygen and nitrogen species and ischemia−reperfusion injury. Mol Aspects Med 2004, 25, 199–210.
  4. Bulkley GB: Free radical mediated reperfusion injury: a selective review. Br J Cancer Suppl 1987, 8, 66–73.
  5. Reilly PM, Schiller HJ, Bulkley GB: Pharmacologic approach to tissue injury mediated by free radicals and other reactive oxygen metabolites. Am J Surg 1991, 161, 488–503.
  6. Guimarães SB, Aragão AA, Santos JM, Kimura Ode S, Barbosa PH, Vasconcelos PR: Oxidative stress induced by torsion of the spermatic cord in young rats. Acta Cir Bras 2007, 22, 30–33.
  7. McCutcheon CA, Orme RM, Scott DA, Davies MJ, McGlade DP: A comparison of dexmedetomidine versus conventional therapy for sedation and hemodynamic control during carotid endarterectomy performed under regional anesthesia. Anesth Analg 2006, 102, 668–675.
  8. Ramsay MA, Luterman DL: Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004, 101, 787–790.
  9. Maier C, Steinberg GK, Sun GH, Zhi GT, Maze M: Neuroprotection by the alpha 2−adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993, 79, 306–312.
  10. Hoffman WE, Kochs E, Werner C, Thomas C, Albrecht RF: Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2−adrenergic antagonist atipamezole. Anesthesiology 1991, 75, 328–332.
  11. Globus MY, Busto R, Dietrich WD, Martinez E, Valdés I, Ginsberg MD: Direct evidence for acute and massive norepinephrine release in the hippocampus during transient ischemia. J Cereb Blood Flow Metab 1989, 9(6), 892–896.
  12. Matsumoto M, Zornow MH, Rabin BC, Maze M: The alpha 2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia−induced increases in striatal norepinephrine concentrations. Brain Res 1993, 627, 325–329.
  13. Jolkkonen J, Puurunen K, Koistinaho J, Kauppinen R, Haapalinna A, Nieminen L, Sivenius J: Neuroprotection by the alpha2−adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol 1999, 372, 31–36.
  14. Snapir A, Posti J, Kentala E, Koskenvuo J, Sundell J, Tuunanen H, Hakala K, Scheinin H, Knuuti J, Scheinin M: Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology 2006, 105, 902–910, quiz 1069–1070.
  15. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193, 265–275.
  16. Wasowicz W, Nève J, Peretz A: Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem 1993, 39, 2522–2526.
  17. Sun Y, Oberley LW, Li Y: A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988, 34(3), 497–500.
  18. Durak I, Yurtarslanl Z, Canbolat O, Akyol O: A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. Clin Chim Acta 1993, 214, 103–104.
  19. Aebi H: Catalase. In: Methods of Enzymatic Analysis. Eds.: Bergmeyer HU, Academic Press, New York, 1974, pp. 673–677. tion of lipid peroxidation, an increase in endogenous antioxidant defense enzymes, and a reduction in tissue NO formation. In the present study, SOD and CAT activities were decreased significantly in group 2 compared with group 1. The tissue malondialdehyde level in ipsilateral testes was increased significantly in group 2 compared with group 1. In group 3, MDA levels were decreased significantly compared with group 2. In addition to these data, the significant increases in SOD and CAT activities in group 3 compared with group 2 point to possible protective effects of dexmede
  20. Cosentino MJ, Nishida M, Rabinowitz R, Cockett AT: Histopathology of prepubertal rat testes subjected to various durations of spermatic cord torsion. J Androl 1986, 7, 23–31.
  21. Turner TT, Bang HJ, Lysiak JJ: Experimental testicular torsion: reperfusion blood flow and subsequent testicular venous plasma testosterone concentrations. Urology 2005, 65, 390–394.
  22. Lysiak JJ, Nguyen QA, Turner TT: Fluctuations in rat testicular interstitial oxygen tensions are linked to testicular vasomotion: persistence after repair of torsion. Biol Reprod 2000, 63, 1383–1389.
  23. Turner TT, Tung KS, Tomomasa H, Wilson LW: Acute testicular ischemia results in germ cell−specific apoptosis in the rat. Biol Reprod 1997, 57, 1267–1274.
  24. Lysiak JJ, Turner SD, Nguyen QA, Singbartl K, Ley K, Turner TT: Essential role of neutrophils in germ cellspecific apoptosis following ischemia/reperfusion injury of the mouse testis. Biol Reprod 2001, 65, 718–725.
  25. Becker EJ Jr, Turner TT: Endocrine and exocrine effects of testicular torsion in the prepubertal and adult rat. J Androl 1995, 16, 342–351.
  26. Turner TT: Acute experimental testicular torsion. No effect on the contralateral testis. J Androl 1985, 6, 65–72.
  27. Filho DW, Torres MA, Bordin AL, Crezcynski−Pasa TB, Boveris A: Spermatic cord torsion, reactive oxygen and nitrogen species and ischemia−reperfusion injury. Mol Aspects Med 2004, 25, 199–210.
  28. Prillaman HM, Turner TT: Rescue of testicular function after acute experimental torsion. J Urol 1997, 157, 340–345.
  29. Boscá L, Hortelano S: Mechanisms of nitric oxide−dependent apoptosis: involvement of mitochondrial mediators. Cell Signal 1999, 11, 239–244.
  30. Ginsberg MD: Neuroprotection in brain ischemia – an update – parts I and II. Neuroscientist 1995, 1, 95–103.
  31. Gutteridge JM: Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995, 41, 1819–1828.
  32. White BC, Grossman LI, Krause GS: Brain injury by global ischemia and reperfusion: a theoretical perspective on membrane damage and repair. Neurology 1993, 43, 1656–1665.
  33. Gertler R, Brown HC, Mitchell DH, Silvius EN: Dexmedetomidine: a novel sedative−analgesic agent. Proc Bayl Univ Med Cent 2001, 14, 13–21.
  34. Hoffman WE, Kochs E, Werner C, Thomas C, Albrecht RF: Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Anesthesiology 1991, 75, 328–332.
  35. Kuhmonen J, Haapalinna A, Sivenius J: Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat. J Neural Transm 2001, 108, 261–271.
  36. Maier C, Steinberg GK, Sun GH, Zhi GT, Maze MB: Neuroprotection by the α2−adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993, 79, 1–7.
  37. Engelhard K, Werner C, Eberspächer E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E: The effect of the alpha 2−agonist dexmedetomidine and the N−methyl−D−aspartate antagonist S(+)−ketamine on the expression of apoptosis−regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003, 96, 524–531.
  38. Eser O, Fidan H, Sahin O, Cosar M, Yaman M, Mollaoglu H, Songur A, Buyukbas S: The influence of dexmedetomidine on ischemic rat hippocampus. Brain Res 2008, 1218, 250–256.
© Wroclaw Medical University